February 18, 2026 · Phase 3 readout
PFE Phase 3 readout: a positive outcome, -1.9%
-1.9%PFIZER (PFE) →
On February 18, 2026, talazoparib plus enzalutamide — PFIZER (Prostate Cancer) reached its Phase 3 readout. The result was a positive outcome, and the stock moved -1.9% in the window around the event. It had already run +9.1% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$27.37
1d before
$27.37
Event day
$26.86
1d after
$27.06
5d after
Pre-catalyst setup
+9.1%
30-day run-up
2407%
30-day volatility
0.6×
volume spike